Plasma immunoreactive calcitonin in lung cancer

B. A. Roos, A. W. Lindall, S. B. Baylin, J. A. O'Neil, A. L. Frelinger, R. S. Birnbaum, P. W. Lambert

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We have measured plasma calcitonin (CT) in 135 untreated eucalcemic men with lung cancer and a control/smoker population. CT levels were determined by RIA and validated by immunoextraction. Plasma immunoreactive CT moieties were purified by immunoadsorbent chromatography, treated with mercaptoethanol and urea, and characterized by gel filtration. Artifacts in human CT RIAs of cancer patient plasma were detected by parallel plasma incubations in a salmon CT RIA system, which does not detect human CT, and by immunoprecipitation of tracer at the end of RIA incubations. Heating fresh plasma to 65 C for 1.5 h reduced RIA artifacts without loss of CT moieties. Such characterization of hypercalcitoninemia in each of the histopathological types of lung cancer has raised some important questions about the interpretation of plasma CT RIA measurements in lung cancer. Based on inhibition of tracer-antibody binding, plasma CT seemed to be elevated in 18% (14 of 80 samples) of the basal plasma samples obtained from patients with epidermoid or anaplastic lung cancer. Unequivocal hypercalcitoninemia (heat stable, causing no inhibition of antibody-tracer binding in the salmon CT RIAs, and immunoextractable with human CT antibodies) was not found in any of the apparently hypercalcitoninemic plasmas from persons with epidermoid or anaplastic lung cancer. By contrast, unequivocal hypercalcitoninemia was found in 27% (15 of 55 samples) of the plasma samples from patients with small cell carcinoma or adenocarcinoma. Most of the immunoreactive CT recovered from small cell and adenocarcinoma lung cancer plasmas with unequivocally elevated CT levels is much larger than the CT monomer.

Original languageEnglish
Pages (from-to)659-666
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume50
Issue number4
StatePublished - Dec 15 1980

Fingerprint

Calcitonin
Lung Neoplasms
Plasmas
salmon calcitonin
Artifacts
Antibodies
Immunosorbents
Small Cell Carcinoma
Mercaptoethanol
Small Cell Lung Carcinoma
Chromatography
Immunoprecipitation
Heating
Gel Chromatography
Urea
Adenocarcinoma
Hot Temperature
Monomers
Gels
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Roos, B. A., Lindall, A. W., Baylin, S. B., O'Neil, J. A., Frelinger, A. L., Birnbaum, R. S., & Lambert, P. W. (1980). Plasma immunoreactive calcitonin in lung cancer. Journal of Clinical Endocrinology and Metabolism, 50(4), 659-666.

Plasma immunoreactive calcitonin in lung cancer. / Roos, B. A.; Lindall, A. W.; Baylin, S. B.; O'Neil, J. A.; Frelinger, A. L.; Birnbaum, R. S.; Lambert, P. W.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 50, No. 4, 15.12.1980, p. 659-666.

Research output: Contribution to journalArticle

Roos, BA, Lindall, AW, Baylin, SB, O'Neil, JA, Frelinger, AL, Birnbaum, RS & Lambert, PW 1980, 'Plasma immunoreactive calcitonin in lung cancer', Journal of Clinical Endocrinology and Metabolism, vol. 50, no. 4, pp. 659-666.
Roos BA, Lindall AW, Baylin SB, O'Neil JA, Frelinger AL, Birnbaum RS et al. Plasma immunoreactive calcitonin in lung cancer. Journal of Clinical Endocrinology and Metabolism. 1980 Dec 15;50(4):659-666.
Roos, B. A. ; Lindall, A. W. ; Baylin, S. B. ; O'Neil, J. A. ; Frelinger, A. L. ; Birnbaum, R. S. ; Lambert, P. W. / Plasma immunoreactive calcitonin in lung cancer. In: Journal of Clinical Endocrinology and Metabolism. 1980 ; Vol. 50, No. 4. pp. 659-666.
@article{160e2a46cb364039bacbe1df582af391,
title = "Plasma immunoreactive calcitonin in lung cancer",
abstract = "We have measured plasma calcitonin (CT) in 135 untreated eucalcemic men with lung cancer and a control/smoker population. CT levels were determined by RIA and validated by immunoextraction. Plasma immunoreactive CT moieties were purified by immunoadsorbent chromatography, treated with mercaptoethanol and urea, and characterized by gel filtration. Artifacts in human CT RIAs of cancer patient plasma were detected by parallel plasma incubations in a salmon CT RIA system, which does not detect human CT, and by immunoprecipitation of tracer at the end of RIA incubations. Heating fresh plasma to 65 C for 1.5 h reduced RIA artifacts without loss of CT moieties. Such characterization of hypercalcitoninemia in each of the histopathological types of lung cancer has raised some important questions about the interpretation of plasma CT RIA measurements in lung cancer. Based on inhibition of tracer-antibody binding, plasma CT seemed to be elevated in 18{\%} (14 of 80 samples) of the basal plasma samples obtained from patients with epidermoid or anaplastic lung cancer. Unequivocal hypercalcitoninemia (heat stable, causing no inhibition of antibody-tracer binding in the salmon CT RIAs, and immunoextractable with human CT antibodies) was not found in any of the apparently hypercalcitoninemic plasmas from persons with epidermoid or anaplastic lung cancer. By contrast, unequivocal hypercalcitoninemia was found in 27{\%} (15 of 55 samples) of the plasma samples from patients with small cell carcinoma or adenocarcinoma. Most of the immunoreactive CT recovered from small cell and adenocarcinoma lung cancer plasmas with unequivocally elevated CT levels is much larger than the CT monomer.",
author = "Roos, {B. A.} and Lindall, {A. W.} and Baylin, {S. B.} and O'Neil, {J. A.} and Frelinger, {A. L.} and Birnbaum, {R. S.} and Lambert, {P. W.}",
year = "1980",
month = "12",
day = "15",
language = "English",
volume = "50",
pages = "659--666",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Plasma immunoreactive calcitonin in lung cancer

AU - Roos, B. A.

AU - Lindall, A. W.

AU - Baylin, S. B.

AU - O'Neil, J. A.

AU - Frelinger, A. L.

AU - Birnbaum, R. S.

AU - Lambert, P. W.

PY - 1980/12/15

Y1 - 1980/12/15

N2 - We have measured plasma calcitonin (CT) in 135 untreated eucalcemic men with lung cancer and a control/smoker population. CT levels were determined by RIA and validated by immunoextraction. Plasma immunoreactive CT moieties were purified by immunoadsorbent chromatography, treated with mercaptoethanol and urea, and characterized by gel filtration. Artifacts in human CT RIAs of cancer patient plasma were detected by parallel plasma incubations in a salmon CT RIA system, which does not detect human CT, and by immunoprecipitation of tracer at the end of RIA incubations. Heating fresh plasma to 65 C for 1.5 h reduced RIA artifacts without loss of CT moieties. Such characterization of hypercalcitoninemia in each of the histopathological types of lung cancer has raised some important questions about the interpretation of plasma CT RIA measurements in lung cancer. Based on inhibition of tracer-antibody binding, plasma CT seemed to be elevated in 18% (14 of 80 samples) of the basal plasma samples obtained from patients with epidermoid or anaplastic lung cancer. Unequivocal hypercalcitoninemia (heat stable, causing no inhibition of antibody-tracer binding in the salmon CT RIAs, and immunoextractable with human CT antibodies) was not found in any of the apparently hypercalcitoninemic plasmas from persons with epidermoid or anaplastic lung cancer. By contrast, unequivocal hypercalcitoninemia was found in 27% (15 of 55 samples) of the plasma samples from patients with small cell carcinoma or adenocarcinoma. Most of the immunoreactive CT recovered from small cell and adenocarcinoma lung cancer plasmas with unequivocally elevated CT levels is much larger than the CT monomer.

AB - We have measured plasma calcitonin (CT) in 135 untreated eucalcemic men with lung cancer and a control/smoker population. CT levels were determined by RIA and validated by immunoextraction. Plasma immunoreactive CT moieties were purified by immunoadsorbent chromatography, treated with mercaptoethanol and urea, and characterized by gel filtration. Artifacts in human CT RIAs of cancer patient plasma were detected by parallel plasma incubations in a salmon CT RIA system, which does not detect human CT, and by immunoprecipitation of tracer at the end of RIA incubations. Heating fresh plasma to 65 C for 1.5 h reduced RIA artifacts without loss of CT moieties. Such characterization of hypercalcitoninemia in each of the histopathological types of lung cancer has raised some important questions about the interpretation of plasma CT RIA measurements in lung cancer. Based on inhibition of tracer-antibody binding, plasma CT seemed to be elevated in 18% (14 of 80 samples) of the basal plasma samples obtained from patients with epidermoid or anaplastic lung cancer. Unequivocal hypercalcitoninemia (heat stable, causing no inhibition of antibody-tracer binding in the salmon CT RIAs, and immunoextractable with human CT antibodies) was not found in any of the apparently hypercalcitoninemic plasmas from persons with epidermoid or anaplastic lung cancer. By contrast, unequivocal hypercalcitoninemia was found in 27% (15 of 55 samples) of the plasma samples from patients with small cell carcinoma or adenocarcinoma. Most of the immunoreactive CT recovered from small cell and adenocarcinoma lung cancer plasmas with unequivocally elevated CT levels is much larger than the CT monomer.

UR - http://www.scopus.com/inward/record.url?scp=0018931860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018931860&partnerID=8YFLogxK

M3 - Article

C2 - 7364923

AN - SCOPUS:0018931860

VL - 50

SP - 659

EP - 666

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -